Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$9.91B |
| 2 |
SPCX
SpaceX
SPCX
|
+$871M |
| 3 |
Eli Lilly
LLY
|
+$719M |
| 4 |
Amazon
AMZN
|
+$698M |
| 5 |
Netflix
NFLX
|
+$627M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$3B |
| 2 |
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
|
+$1.54B |
| 3 |
TSMC
TSM
|
+$1.42B |
| 4 |
NVIDIA
NVDA
|
+$1.41B |
| 5 |
SNDK
Sandisk
SNDK
|
+$771M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 82.67% |
| 2 | Technology | 3.92% |
| 3 | Healthcare | 2.55% |
| 4 | Industrials | 2.24% |
| 5 | Financials | 2.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONCY
13351
Oncolytics Biotech
ONCY
$99.5M
| $18.8K | ﹤0.01% |
19,813
+1,875
| +10% | +$1.74K |
|
13352
CALL
CXApp
CXAI
$6.03M
| $18.8K | ﹤0.01% |
2,020
+290
| +17% | +$2.67K |
|
13353
CollPlant Biotechnologies
CLGN
$6.43M
| $18.7K | ﹤0.01% |
5,370
+2,153
| +67% | +$8.29K |
|
|
ACCL
13354
Acco Group Holdings
ACCL
$41.6M
| $18.7K | ﹤0.01% |
11,139
+477
| +4% | +$715 |
|
13355
PUT
ABVC BioPharma
ABVC
$28.5M
| $18.3K | ﹤0.01% |
+11,600
| New | +$14.4K |
|
|
BNBX
13356
DELISTED
BNB PLUS CORP
BNBX
| $18.3K | ﹤0.01% |
52,243
-9,597
| -16% | -$4.74K |
|
|
PWCM
13357
PowerCompute Inc
PWCM
$1.67M
| $18.3K | ﹤0.01% |
4,892
+2,886
| +144% | +$16.9K |
|
|
PPCB
13358
Propanc Biopharma
PPCB
$1.87M
| $18.1K | ﹤0.01% |
+12,090
| New | +$26.1K |
|
13359
CDT Equity Inc
CDT
$2.78M
| $18.1K | ﹤0.01% |
+3,230
| New | +$66.9K |
|
13360
Maris-Tech
MTEK
$10.7M
| $18K | ﹤0.01% |
+18,344
| New | +$23.4K |
|
13361
PUT
Entera Bio
ENTX
$495M
| $17.9K | ﹤0.01% |
+10,100
| New | +$12.6K |
|
13362
E-Power Inc
EPOW
$10.5M
| $17.7K | ﹤0.01% |
+28,963
| New | +$20.3K |
|
13363
MIRA Pharmaceuticals
MIRA
$30M
| $17.7K | ﹤0.01% |
+18,661
| New | +$18.9K |
|
|
ETS
13364
Elite Express Holding Inc
ETS
$92.1M
| $17.5K | ﹤0.01% |
20,568
-41,891
| -67% | -$25.3K |
|
13365
Quetta Acquisition Corp Right
QETAR
| $17.4K | ﹤0.01% |
24,865
-28,129
| -53% | -$25.1K |
|
|
REE
13366
DELISTED
REE Automotive
REE
| $17K | ﹤0.01% |
86,891
-109,406
| -56% | -$49.9K |
|
13367
Telomir Pharmaceuticals
TELO
$80.5M
| $17K | ﹤0.01% |
+13,266
| New | +$17.3K |
|
|
NWTG
13368
Newton Golf Co
NWTG
$6.02M
| $16.9K | ﹤0.01% |
+20,133
| New | +$22.8K |
|
13369
PUT
Cardiff Oncology
CRDF
$104M
| $16.9K | ﹤0.01% |
+13,000
| New | +$20.6K |
|
|
CYPH
13370
PUT
Cypherpunk Technologies Inc
CYPH
$239M
| $16.7K | ﹤0.01% |
27,300
-43,500
| -61% | -$39.7K |
|
13371
CALL
Nerdy
NRDY
$74.8M
| $16.7K | ﹤0.01% |
1,213
-10,160
| -89% | -$133K |
|
13372
CALL
Neuronetics
STIM
$213M
| $16.6K | ﹤0.01% |
+12,800
| New | +$18.6K |
|
|
BTLN
13373
CALL
Brightline Interactive
BTLN
$15.9M
| $16.6K | ﹤0.01% |
21,600
-117,500
| -84% | -$78.8K |
|
|
STEX
13374
PUT
Streamex Corp
STEX
$67.3M
| $16.6K | ﹤0.01% |
19,500
-96,100
| -83% | -$99.4K |
|
|
CCUP
13375
PUT
T-REX 2X Long CRCL Daily Target ETF
CCUP
$40.6M
| $16.5K | ﹤0.01% |
+1,110
| New | +$48.5K |
|
Similar funds
Citadel Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Citadel Advisors held 15,445 positions worth $875B, up 41% from $618B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Citadel Advisors's Q2 2026 filing shows 2,573 new, 6,088 increased, 4,803 reduced and 1,873 closed positions. Its largest new stake was SpaceX: 5,129,884 shares worth $876M. The largest sale was Micron Technology, an estimated $3B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, up from 79% a quarter earlier, followed by Technology and Healthcare.
- Citadel Advisors's largest Q2 2026 buy was SpaceX: 5,129,884 shares worth $876M.
- Citadel Advisors added most to iShares Core S&P 500 ETF in Q2 2026, an estimated $9.91B increase.
- Citadel Advisors's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $3B.
- Citadel Advisors fully exited iShares 7-10 Year Treasury Bond ETF in Q2 2026, selling an estimated $325M.
- Citadel Advisors's ten largest holdings make up 23% of its $875B portfolio in Q2 2026.
- Citadel Advisors opened 2,573 new positions and closed 1,873 in Q2 2026.
- Citadel Advisors's portfolio value rose 41% quarter-over-quarter to $875B.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.